JNJ 10229570 AAA

Drug Profile

JNJ 10229570 AAA

Alternative Names: JNJ-10229570; JNJ-10229570-AAA; MC 5 - Ortho Dermatologics; MC5-RA - Ortho Dermatologics

Latest Information Update: 02 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ortho Dermatologics
  • Developer Valeant Pharmaceuticals International
  • Class Antiacnes
  • Mechanism of Action Melanocortin type 5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acne vulgaris

Most Recent Events

  • 27 Jul 2017 Valeant Pharmaceuticals International acquired Ortho Dermatologics in 2011 and changed the name of the later to Valeant Dermatology. Subsequently, in July 2017, it was rebranded to Ortho Dermatologics
  • 12 Dec 2011 Valeant Pharmaceuticals acquires Ortho Dermatologics
  • 29 Nov 2011 Johnson and Johnson completes enrolment in its phase II trial for Acne vulgaris in USA (NCT01326780)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top